High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study

Gregor Novak

doi:10.1080/00365521.2025.2597263

December 8, 2025Scandinavian Journal of Gastroenterology

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study

View Full Paper

Ask AI

Bookmark

Share

Key Points

Ustekinumab achieves substantial rates of clinical remission in patients with inflammatory bowel disease, and
The therapy is associated with notable rates of both biochemical and endoscopic remission in this cohort,
Observational analysis of treatment outcomes reflects real-world experiences with ustekinumab in IBD management,
These findings support ustekinumab's potential as a first-line biological treatment for IBD.

Implication

Cohort study reveals ustekinumab leads to high treatment-persistence and significant clinical outcomes in inflammatory bowel disease.

Abstract

First-line treatment with ustekinumab demonstrates high treatment-persistence and is associated with substantial rates of clinical, biochemical, and endoscopic remission in patients with IBD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gregor Novak (2025) studied this question.

synapsesocial.com/papers/694020e22d562116f28faaee https://doi.org/10.1080/00365521.2025.2597263

View Full Paper

Ask AI

Bookmark

Share

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study

Key Points

Implication

Abstract

Discussion

Cite This Study

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading